The drugs side effects are usually short-lived and include headache, nausea, and diarrhea (Liu 2011
Dietary protein for athletes: from requirements to optimum adaptation
With NAFLD affecting 2530% of the global population, up to 6070% of people with type 2 diabetes and almost all individuals with severe obesity [9, 10], an available pharmacotherapy for NAFLD is highly warranted
The FDA approves Novo Nordisks Wegovy, another GLP-1 medication, for the use of weight loss
Private insurers are also reevaluating their coverage policies due to ongoing supply shortages and increased off-label use of these medications
A conversation with your provider about your metabolic baseline, risk factors, and genetic predispositions can help determine whether GLP-1 therapy is right for you and which formulation may best support your goals